WuXi PharmaTech Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan

SHANGHAI, Sept. 17, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has been awarded the 2015 Frost & Sullivan North American Open-Access R&D Technology Leadership Award. The award is part of Frost & Sullivan's Growth, Innovation & Leadership Award series, recognizing companies that have demonstrated excellence in devising and implementing strong growth strategies.

WuXi was recognized for its outstanding achievement and strong performance in helping its customers improve their R&D productivity while reducing cost through a model of R&D enablement. Together with over 2,000 partners worldwide, WuXi is advancing breakthroughs in science and medicine that help people around the world lead happier and healthier lives. Frost & Sullivan views WuXi as an innovator in business relationships across the entire pharmaceutical and biotechnology value chain. 

"We thank Frost & Sullivan for recognizing WuXi's diligent efforts in building an open-access R&D enabling platform," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "We also thank our customers and collaborative partners for their trust and support in our journey. WuXi is honored to play an important role in helping to bring better medicines to patients faster."

About WuXi PharmaTech

WuXi PharmaTech is a research-driven and customer-focused company, providing pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. The company is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi has the first whole CMC platform in China inspected by the U.S. FDA; the first cGMP biologics manufacturing facility in China that is compliant with U.S., European and Chinese regulatory standards; the first GLP preclinical laboratory in China that is double certified with an OECD country and CFDA; the first GLP/GCP bioanalytical laboratory in China that has passed U.S. FDA, OECD, and CFDA inspections; and the first CLIA-certified clinical genomics lab in China. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.   

About Frost & Sullivan Growth, Innovation & Leadership Awards

Frost & Sullivan Growth, Innovation & Leadership Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry. This research is an invaluable source to companies for new ideas to improve strategies and processes, which ultimately drive corporate growth. These achievements are recognized at the Frost & Sullivan Growth, Innovation & Leadership Awards Gala. 

For more information, please contact:

WuXi PharmaTech
Ronald Aldridge (for investors)
LaVoieHealthScience
T: +1-617-374-8800 x109
M: +1 617-792-2459
[email protected]

Aaron Shi (for the media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
[email protected]  

SOURCE WuXi PharmaTech (Cayman) Inc.

Related Links

http://www.wuxiapptec.com